Parsonex Advisory Services’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Parsonex Advisory Services's VRTX Position: Q3 2026 in Review
Parsonex Advisory Services opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2026: 549 shares worth $287K. The stake represents 0.21% of the portfolio and ranks #48 among its holdings. This is a return to the name: Parsonex Advisory Services previously reported a position in VRTX as recently as Q1 2026.
Parsonex Advisory Services first reported a position in VRTX in Q2 2025 and has held it in 5 quarters since. The position peaked at $467K in Q4 2025. 1,793 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.
- Parsonex Advisory Services held 549 shares of Vertex Pharmaceuticals worth $287K as of Q3 2026.
- Vertex Pharmaceuticals was a new Parsonex Advisory Services position in Q3 2026.
- Vertex Pharmaceuticals made up 0.21% of Parsonex Advisory Services's portfolio in Q3 2026, its #48 holding.
- Parsonex Advisory Services first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
- Parsonex Advisory Services's Vertex Pharmaceuticals position peaked at $467K in Q4 2025.
- 1,793 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.
Based on Parsonex Advisory Services's 13F filing for Q3 2026, filed 13 Nov 2026.